Cheminformatics driven development of novel ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Cheminformatics driven development of novel therapies for drug resistant prostate cancer
Auteur(s) :
Ban, Fuqiang [Auteur]
Dalal, Kush [Auteur]
Leblanc, Eric [Auteur]
Morin, Helene [Auteur]
Rennie, Paul S. [Auteur]
Cherkasov, Artem [Auteur]
Dalal, Kush [Auteur]
Leblanc, Eric [Auteur]

Morin, Helene [Auteur]
Rennie, Paul S. [Auteur]
Cherkasov, Artem [Auteur]
Titre de la revue :
Molecular informatics
Nom court de la revue :
Mol Inform
Date de publication :
2018-05-07
ISSN :
1868-1751
Mot(s)-clé(s) :
drug resistance
prostate cancer
Androgen receptor
cheminformatics
antiandrogen
prostate cancer
Androgen receptor
cheminformatics
antiandrogen
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Androgen receptor (AR) is a master regulator of prostate cancer (PCa), and therefore is a pivotal drug target for the treatment of PCa including its castration-resistance form (CRPC). The development of acquired resistance ...
Lire la suite >Androgen receptor (AR) is a master regulator of prostate cancer (PCa), and therefore is a pivotal drug target for the treatment of PCa including its castration-resistance form (CRPC). The development of acquired resistance is a major challenge in the use of the current antiandrogens. The recent advancements in inhibiting AR activity with small molecules specifically designed to target areas distinct from the receptor's androgen binding site are carefully discussed. Our new classes of AR inhibitors of AF2 and BF3 functional sites and DBD domains designed using cheminformatics techniques are promising to circumvent various AR-dependent resistance mechanisms.Lire moins >
Lire la suite >Androgen receptor (AR) is a master regulator of prostate cancer (PCa), and therefore is a pivotal drug target for the treatment of PCa including its castration-resistance form (CRPC). The development of acquired resistance is a major challenge in the use of the current antiandrogens. The recent advancements in inhibiting AR activity with small molecules specifically designed to target areas distinct from the receptor's androgen binding site are carefully discussed. Our new classes of AR inhibitors of AF2 and BF3 functional sites and DBD domains designed using cheminformatics techniques are promising to circumvent various AR-dependent resistance mechanisms.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
INSERM
Université de Lille
Université de Lille
Date de dépôt :
2022-06-15T13:58:38Z